| Obesity
Foundayo vs Wegovy
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Foundayo vs Wegovy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWegovy has a higher rate of injection site reactions vs Foundayo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wegovy but not Foundayo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Foundayo
Wegovy
At A Glance
Oral
Daily
GLP-1 receptor agonist
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Obesity
- Obesity
- Nonalcoholic Steatohepatitis
Dosing
Obesity Start at 0.8 mg orally once daily; escalate to 2.5 mg, then 5.5 mg, then optionally to 9 mg, 14.5 mg, or 17.2 mg (maximum) once daily, increasing at intervals of at least 30 days based on tolerability; take with or without food; swallow tablets whole.
Obesity Adults: maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg; pediatric patients aged 12 years and older: 2.4 mg (or 1.7 mg) SC injection once weekly.
Nonalcoholic Steatohepatitis 2.4 mg SC injection once weekly (maintenance) after escalation from 0.25 mg; may reduce to 1.7 mg once weekly if 2.4 mg not tolerated.
Cardiovascular risk reduction Maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Known serious hypersensitivity to orforglipron or any excipient in FOUNDAYO
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or to any excipient in WEGOVY injection or WEGOVY tablet
Adverse Reactions
Most common (>=5%) Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair loss
Serious Thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, hair loss, dysesthesia
Serious Risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during anesthesia
Postmarketing Acute pancreatitis and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, rash, urticaria, pulmonary aspiration, acute kidney injury
Pharmacology
Orforglipron is a small-molecule GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor, reducing appetite and caloric intake by activating GLP-1 receptors in brain regions that regulate appetite and food intake, and also delays gastric emptying.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor, regulating appetite and caloric intake, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Foundayo
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (0/12) · Qty limit (0/12)
Wegovy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Foundayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Wegovy
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Foundayo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Wegovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$149/momo
Foundayo Self-Pay Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$349/momo
Wegovy Self-Pay Program - InjectableCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FoundayoView full Foundayo profile
WegovyView full Wegovy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.